Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval
Pfizer and Gilead Seen As Suitors
Executive Summary
John Thero insists company is focused on approval and launch, as interest in European rights grow.
You may also be interested in...
Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss
A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.
Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain
First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.
New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
The addressable patient population in the US could increase by 4.5 million if new trial is successful.